New research published today in the journal Pediatric Blood and Cancer shows how early cancer screening and surveillance in patients with Li-Fraumeni Syndrome (LFS) results in additional years of life, and is cost effective for third-party payers.
Jon M. Huntsman, Sr. was a visionary philanthropist who made it his personal mission to eradicate cancer from the face of the Earth. He often described his devastation after the loss of several family members and close friends to the disease. In the 1990s, he received his first of four cancer diagnoses. His personal experiences with cancer ignited a determination to make a difference. After he completed treatments, Huntsman and his family vowed to use their considerable means to transform the experience for cancer patients and to advance research. Vision began its course to reality with the founding a cancer center that would bear the Huntsman family name.
Peter Huntsman, CEO of the Huntsman Foundation and chairman and CEO of the Huntsman Cancer Foundation (HCF), announced today a transformational $30 million gift from the family’s foundation. This donation allows Huntsman Cancer Institute (HCI) at the University of Utah (U of U) to better plan for and address the future needs of cancer patients in the Mountain West. The gift is in addition to the $40 million already raised by HCF to support the construction of the Kathryn F. Kirk Center for Comprehensive Cancer Care and Women’s Cancers at Huntsman Cancer Institute.
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) contributed to the development of a global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes. This resource, called the BRCA Exchange, is now available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health (GA4GH) to enhance sharing of BRCA1/BRCA2 data. The new resource will allow clinicians to review expert classifications of variants in these major cancer predisposition genes as part of their individual assessment of cancer prevention, screenings, and interventions for patients at higher risk for breast, ovarian, and certain other cancers.
Huntsman Cancer Foundation (HCF) announces that several individuals and business organizations have committed a total of $40 million to support a proposed major building expansion of Huntsman Cancer Institute (HCI) at the University of Utah (U of U).
YWCA Utah has selected Mary Beckerle, PhD, CEO of Huntsman Cancer Institute (HCI) at the University of Utah (U of U) to receive the Outstanding Achievement Award in Medicine and Health. Beckerle will be honored today at the 30th annual YWCA Utah LeaderLuncheon.
Scientists at Huntsman Cancer Institute (HCI) at the University of Utah (U of U), in collaboration with the Salk Institute for Biological Studies, have generated the first single cell resolution atlas of genes that control the formation of breast tissue. The atlas provides a comprehensive molecular map that will be used to help researchers understand how breast cancers form and to pinpoint new ways to prevent, diagnose, and treat the disease.
Huntsman Cancer Institute (HCI) at the University of Utah today announced the appointment of Cornelia Ulrich, PhD, MS, as director of its National Cancer Institute-Designated Comprehensive Cancer Center. She will oversee HCI’s academic consortium of nearly 200 cancer research teams. Ulrich will lead efforts to advance HCI’s research in laboratory, clinical and population science, with the goal of improving cancer prevention and treatment. – Huntsman Cancer Institute (HCI) at the University of Utah today announced the appointment of Cornelia Ulrich, PhD, MS, as director of its National Cancer Institute-Designated Comprehensive Cancer Center. She will oversee HCI’s academic consortium of nearly 200 cancer research teams. Ulrich will lead efforts to advance HCI’s research in laboratory, clinical and population science, with the goal of improving cancer prevention and treatment.
Huntsman Cancer Institute (HCI) physician-scientist Ahmad Halwani, MD, has been selected by the National Cancer Institute (NCI) to receive a Cancer Clinical Investigator Team Leadership Award. This award recognizes physician-scientists for their contributions to clinical cancer research. It also provides financial support for ongoing research and leadership development to enable recipients to further advance their clinical research careers.
Nearly 80 million Americans — one out of every four people — are infected with human papillomavirus (HPV). And of those millions, more than 31,000 will be diagnosed with an HPV-related cancer this year. Despite those staggering figures and the availability of a vaccine to prevent the infections that cause these cancers, HPV vaccination remains low in the United States.
Often what kills cancer patients is not the cancer at its original or primary site, but its spread to secondary sites within the body, through a process called metastasis. In the case of breast cancer, the tumor often spreads to the bone, and it is this bone metastasis that results in intense pain and precedes spread to other organs.
Huntsman Cancer Institute announced today that it has been certified to offer both chimeric antigen receptor (CAR) T cell therapies recently approved by the U.S. Food and Drug Administration. The therapies are approved for types of aggressive blood cancers, including B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. HCI is one of a few locations nationwide, and the only in the Mountain West, approved to offer these new therapies to adult cancer patients.
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) today announced the opening of the Cancer Population Sciences and Huntsman Center for Health Outcomes and Population Equity (HOPE), a new research and clinical space dedicated to preventing cancer and improving health among underserved populations and improving outcomes in cancer patients. The center recently received $9.7 million from the Patient-Centered Outcomes Research Institute (PCORI) to fund a clinical trial researching new and effective approaches to reduce tobacco use.
Gliomas are the most common type of central nervous system cancer but how these tumors develop is not fully understood. Sheri Holmen, PhD a researcher at Huntsman Cancer Institute (HCI) and professor of surgery at the University of Utah just published the results of her research on gliomas in Cell Reports. The work is focused on a mutated gene that is a critical piece of the puzzle for glioma development, according to Holmen’s work.
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.
New research from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) indicates steroid and hormone receptors are simultaneously active in many endometrial cancer tissues. The findings, published today in the journal Cell Reports, yield insights about factors that contribute to more aggressive endometrial tumors.
The Board of Directors of Huntsman Cancer Foundation has elected Peter R. Huntsman as Chairman of the Board effective immediately. He replaces his father, Jon M. Huntsman, Sr., who founded Huntsman Cancer Institute (HCI) and was its principal benefactor. Jon M. Huntsman passed away earlier this month.
New research from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) illuminates aspects of how an early embryo, the product of fertilization of a female egg cell by a male sperm cell, can give rise to all the many cell types of the adult animal. The findings, published today in the journal Cell, have significant implications for understanding how early development is orchestrated, and provides a mechanism for how parental environment might impact the expression of these genes in the offspring.
We are truly saddened at the passing of our remarkable founder and benefactor, Jon M. Huntsman, this afternoon. He passed away peacefully at home, surrounded by his loving family. Other than his family, his greatest passion was to eradicate cancer. We will honor his legacy by continuing to provide hope and healing to all impacted by this disease.